Michael S Khodadoust
City of Hope Comprehensive Cancer Center LAO · Cancer Immunotherapy Trials Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael S Khodadoust as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:31 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04541017 · Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentNational Cancer Institute (NCI) · terminated · Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome · principal investigator
- Ph2NCT03063632 · Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial SarcomaNational Cancer Institute (NCI) · completed · Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2018 to 2026Named on NCT04541017
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT03063632
- U01CA154967RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT03063632
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:31 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.J Clin Oncol · 2020210 citationsRCR 9.0
- Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.Nat Commun · 2021191 citationsRCR 8.4
- 132 citationsRCR 5.1
- 99 citationsRCR 21.9
- Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.J Exp Med · 202033 citationsRCR 1.1
- Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.Leuk Lymphoma · 202512 citationsRCR 3.5